Pharmaceutical company Bioiberica Farma places at the disposal of the journalist community complete information about the company’s operations, up-to-date news and the latest trends in osteoarthritis. The ‘Osteoarthritis Agenda’ section will list the most important congresses dealing with this disease, such as the World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases that is going to be held the coming 20th of January.
This rheumatic disease affects 24% of Spaniards aged 45 and older It is estimated that by 2020 osteoarthritis will become the fourth most common cause of disability because of the population’ longer life expectancy and progressive ageing. Apart from ageing, the other factors leading to the development of osteoarthritis are obesity, genetic predisposition and joint overuse. The role of family physicians is fundamental in the early detection of osteoarthritis because they are the medicine professionals most frequently consulted by the general population.
MOVES is a new multicenter clinical essay involving 560 patients from Spain, Germany, France and Poland.
The aim of the MOVES project (Multicenter Osteoarthritis InterVEntion trial with Sysadoas) is to contribute further evidence of the efficacy and security of the combination of chondroitin sulfate and glucosamine in the treatment of knee osteoarthritis patients with moderate to severe pain.
The general manager of Bioiberica highlighted his company’s commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients’ quality of life.
* This website is not intended to report adverse events related to Bioiberica's products. If you would like to report a suspected adverse reaction, please contact the Department of Pharmacovigilance Bioiberica.